Outlook Therapeutics (OTLK) News Today $5.28 +0.05 (+0.96%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comCautious Outlook on United Therapeutics Amid Revenue Growth and Competitive PressuresNovember 1, 2024 | markets.businessinsider.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Buy" by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target aOctober 30, 2024 | marketbeat.comULM College of Business and Social Sciences to host Outlook Summit at Bayou Pointe Event Center on November 8October 29, 2024 | msn.comPositive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity ProgramOctober 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry ShiftsOctober 19, 2024 | markets.businessinsider.comOutlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG ResearchBTIG Research reiterated a "buy" rating and set a $50.00 target price on shares of Outlook Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comOutlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentOctober 17, 2024 | finance.yahoo.comEconomic Outlook Conference will “Re-Imagine” the future of the Ohio ValleyOctober 12, 2024 | msn.comOutlook down? Microsoft confirms issues with email service, but a fix is now hereOctober 12, 2024 | yahoo.comWeekend Weather Outlook: Tri-Cities heat up again for a warm, sunny weekendOctober 12, 2024 | yahoo.comIs Outlook down? Thousands report Microsoft 365 issuesOctober 12, 2024 | news.yahoo.comOUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 11, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by BrokeragesShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among analysOctober 5, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) CFO Purchases $28,450.00 in StockOctober 1, 2024 | insidertrades.comOutlook: How to add or remove birthdays from your calendarSeptember 28, 2024 | yahoo.comRevenera’s Monetization Monitor 2025 Outlook Highlights Opportunities to Drive ProfitabilitySeptember 26, 2024 | finance.yahoo.com5 Reasons Why I Schedule My Outlook EmailsSeptember 26, 2024 | yahoo.comViking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of DataSeptember 25, 2024 | seekingalpha.comMicrosoft Outlook: Best tips and tricks I use to manage my inbox efficientlySeptember 25, 2024 | msn.comGreat Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Great Point Partners LLC lifted its stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 15.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,701,510 shares of the company's stock after buying an additional 221,5September 24, 2024 | marketbeat.comManage Your Outlook Attachments Like a Pro with These 8 TipsSeptember 23, 2024 | msn.comIntegrated Financial Technologies to Sponsor Auto Finance Summit Market Outlook SessionSeptember 23, 2024 | finance.yahoo.comNielsenIQ Mid-Year Consumer Outlook: Guide to 2025 Reveals Catalysts to Change in Key Verticals Across IndustriesSeptember 23, 2024 | finance.yahoo.comAtlantic Tropical Outlook: South may be impacted by a Gulf stormSeptember 21, 2024 | msn.comThe New Outlook for Windows Isn't Worth Using: 8 Improvements It NeedsSeptember 19, 2024 | msn.comWindows’ new Outlook app: 4 key details you absolutely need to knowSeptember 19, 2024 | msn.comEvilginx Gmail And Outlook Attacks Can Bypass 2FA, Security Expert WarnsSeptember 19, 2024 | forbes.comThird-party email apps are about to lose access to Outlook emailsSeptember 17, 2024 | msn.comOutlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesSeptember 16, 2024 | globenewswire.comOutlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference SeriesSeptember 13, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target amoSeptember 10, 2024 | marketbeat.comBuy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/LytenavaSeptember 5, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical TrialSeptember 4, 2024 | globenewswire.comOutlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comAscendiant Capital Markets Cuts Outlook Therapeutics (NASDAQ:OTLK) Price Target to $33.00Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday.September 3, 2024 | marketbeat.comOutlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA HurdlesAugust 26, 2024 | seekingalpha.comVanguard Group Inc. Has $4.08 Million Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK)Vanguard Group Inc. lessened its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 94.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 341,300 shares of the company's stock after selliAugust 19, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post FY2024 Earnings of ($3.90) Per ShareOutlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Investment analysts at Brookline Capital Management lowered their FY2024 earnings per share estimates for shares of Outlook Therapeutics in a research report issued on Wednesday, August 14th. Brookline Capital Management analyst K. DolliverAugust 19, 2024 | marketbeat.comOutlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comOutlook Therapeutics (NASDAQ:OTLK) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reiterated a "buy" rating and set a $53.00 target price on shares of Outlook Therapeutics in a research report on Friday.August 16, 2024 | marketbeat.comBrokers Offer Predictions for Outlook Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:OTLK)Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Research analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Outlook Therapeutics in a research report issued on Thursday, August 15th. HC Wainwright analyst D. Tsao now anticipates that the company willAugust 16, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the cAugust 16, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday.August 15, 2024 | marketbeat.comOutlook Therapeutics Poised for Growth: Strong Buy Recommendation Amidst Positive Clinical and Financial DevelopmentsAugust 15, 2024 | markets.businessinsider.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Q3 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deOTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024August 14, 2024 | investorplace.comOutlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comOptimistic Outlook: Jasper Therapeutics’ Clinical Advances and Market PotentialAugust 14, 2024 | markets.businessinsider.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.000.45▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼04▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Coherus BioSciences News Today Champions Oncology News Today Protara Therapeutics News Today Mereo BioPharma Group News Today Arcturus Therapeutics News Today Y-mAbs Therapeutics News Today Zevra Therapeutics News Today ProKidney News Today Esperion Therapeutics News Today REGENXBIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
